Hypertension
Conditions
Keywords
Hypertension
Brief summary
The aim of present study is to evaluate the efficacy and safety of Extended-Release Carvedilol Sulfate versus in Patients With Mild or Moderate Primary Hypertension
Interventions
Sponsors
Jiangsu HengRui Medicine Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Males or Females * Aged from 18 to 70 years * Had a history of essential hypertension * Average sitting diastolic blood pressure≧90mmHg，but≦109mmHg
Exclusion criteria
* Malignant hypertension * Average sitting systolic blood pressure≧180mmHg * Type 2 diabetes with hemoglobin A1c≥9% * Type 1 diabetes * New York Heart Association class Ⅱ-Ⅳ congestive heart-failure * Unstable angina * Second or third degree heart block or history of sick sinus syndrome unless a pacemaker was in place * Atrial fibrillation * Bradycardia (\<60 bpm, seated) * Asthma or other obstructive pulmonary disease * History of myocardial infarction * Stroke in the 6 months before screening * Known contraindications to β-adrenergic blocker therapy * Glutamic-oxaloacetic transaminase and/or glutamic-pyruvic transaminase\>3 times upper limit of normal * Crea\>2 times upper limit of normal * Pregnancy or lactation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mean Change From Baseline in Sitting Diastolic Blood Pressure (sDBP) at Week 8 | Baseline and Week 8 |
Secondary
| Measure | Time frame |
|---|---|
| Mean Change From Baseline in Sitting Systolic Blood Pressure (sSBP) at Week 8 | Baseline and Week 8 |
| Proportion of Patients With Sitting Systolic Blood Pressure <140 mm Hg and Sitting Diastolic Blood Pressure <90 mm Hg at Week 8 | Week 8 |
Countries
China
Contacts
Primary ContactYun Zhang, Professor
Outcome results
None listed